TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK
Shares of TG Therapeutics $TGTX rocketed up 64% this morning after the New York-based biotech reported that its lead cancer drug scored a win in Phase III. And now the biotech plans to pursue an accelerated approval at the FDA.
Investigators say that TG-1101 (ublituximab), their anti-CD20 monoclonal antibody, plus Imbruvica beat Imbruvica alone in treating high-risk chronic lymphocytic leukemia, or CLL. The combination arm scored an overall response rate of 80% compared to only 47% in the solo drug arm. A total of 126 patients were recruited for the Phase III.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.